BioScript Inc (BIOS): Rallied 15% Today on Zero News

Steve Kanaval  |

BioScrip, Inc. (BIOS) rallied 15% today on zero news. I have a call into the company to find out what they think. I tell you what I think. The stock tanked when they missed earnings on Election Day falling from $2.60 to $1.00 and this is the bounce back from that miss. I can see shares trading back to $1.90 area as part of a technical bounce, and close above this calls for a retest the $2.50 - $2.60 level where they fell on an election earnings miss - this may take the rest of the quarter. I think this is the only stock that went lower on Election Day :)

I like what they do, but want to learn more about the biz back with more on them

I also noticed they had as many insider buys in last 90 days as entire year...something seems afoot, as price always tells the story.

BioScrip, Inc. (BIOS) provides home infusion services in the United States. The company engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. It is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. BioScrip, Inc. offers its services at patient’s homes, outpatient clinics, nursing facilities, physician’s offices, and ambulatory infusion centers. The company markets and sells its products and services through sales and marketing representatives, payor relationships, and other government programs. BioScrip, Inc. was founded in 1993 and is based in Denver, Colorado.

I have no position in this stock nor are we paid by the company

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Market Movers

Sponsored Financial Content